We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Denies Approval of Takeda’s Natpara in Complete Response Letter
FDA Denies Approval of Takeda’s Natpara in Complete Response Letter
Takeda Pharmaceuticals has received a Complete Response Letter from the FDA denying its Prior Approval Supplement (PAS) application for Natpara (parathyroid hormone) for chronic hypoparathyroidism.